BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.66 USD
+0.01 (1.87%)
Updated Sep 20, 2024 03:58 PM ET
After-Market: $0.66 0.00 (-0.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 21 - 40 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q21 Results; Motixafortide Marches Towards NDA Filing in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
GENESIS Phase 3 Data Details Pretty Darn Impressive; NDA Expected in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2020 Results; First NDA in Sight; We Believe Also a Meaningful Partnership; Target Adjusted to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
COMBAT Gives a Big Bloody Nose to Pancreatic Cancer; Target Increased to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q20 Results; Motixafortide Could Be the Champion of 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
COMBAT Approaching DEFCON 1 Against Pancreatic Cancer; Major Catalyst Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2019 Results; Mid-2020 Pancreatic Survival Data Critical to Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
COMBAT Fully Enrolls; Key Survival Data Mid-2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Patience Appears to Be Paying off for COMBAT; Looking Forward to Next Steps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Nice COMBAT First Look at Analyst Day Preps for ESMO Oral Next Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q19 Results; All Eyes on December 13 COMBAT Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q19 Results; BL-8040 Marching Towards Key Data in 2H19; Adjusting Post-Split Target to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q19 Results; GENESIS Pushes Forward; Interim COMBAT Data Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2018 Results; BL-8040 Profile Continues to Build Nicely; Target Adjusted to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Investor Day Highlights BL-8040 Promise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q18 Results; Continuing to Push BL-8040 Down the Field
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Pushing the Boulder Further up the Pancreatic Mountain
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Locking In More ''8040 Economics and Previewing COMBAT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q18 Results; Getting Close to Significant Inflection Points; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J